With less than three weeks until Americans cast their vote, what would healthcar...
The US FDA has approved AbbVie's VYALEV to treat motor fluctuations in adults wi...
An FDA AdCom in September recommended against full approval for Ocaliva by a 13-...
A Phase IIb/III trial with infants entering their first respiratory syncytial vi...
The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which h...
An 800% increase in licensing deal values indicates growing confidence in mRNA t...
Radiopharm Theranostics (RAD) and AtomVie have announced a partnership for the d...
Strategic restructuring will support the ongoing launch of the oral postpartum d...
Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety ...
Fresenius Kabi and Cellular Origins have announced a partnership to advance cell...
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial...
Acadia Pharmaceuticals has received marketing authorisation from Health Canada f...
Lexicon Pharmaceuticals has entered a licensing agreement with Viatris to commer...
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience po...
Lilly’s senior VP of information and R&D IT Ramesh Durvasula said Lilly will use...
bit.bio’s method for pluripotent stem cell (PSC) programming, opti-ox, was deeme...
